Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Barclays Downgrades Replimune Group (REPL) to Equalweight
July 22, 2025 4:31 PM EDTBarclays analyst Peter Lawson downgraded Replimune Group (NASDAQ: REPL) from Overweight to Equalweight with a price target of $3.00 (from $17.00).
The analyst comments "Downgrade to Equal Weight and lower PT to $3 following the surprising CRL issued by FDA for RP1+PD1 combo, which places... More
Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'
July 22, 2025 10:20 AM EDTLeerink Partners analyst Jonathan Chang reiterated an Outperform rating and $21.00 price target on Replimune Group (NASDAQ: REPL)
The analyst comments "Bottom Line: The FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec; GALV, GM-CSF oncolytic virus) + nivolumab in anti-PD-1-failed melanoma. This update will likely come as a... More
Mizuho Desk Comments on Replimune (REPL)
July 22, 2025 8:52 AM EDTMizuho Desk Comments on Replimune (NASDAQ: REPL)
The analyst comments "REPL. Stock clobbered on CRL. This came up a few times last month at investor meetings on unfavorable risk/reward into the PDUFA. Playing out nicely this morning for those... More
Replimune receives FDA rejection letter for melanoma treatment
July 22, 2025 7:03 AM EDTReplimune Group, Inc. (NASDAQ: REPL) received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its application for RP1 in combination with nivolumab for treating advanced melanoma.
The FDA stated the IGNYTE trial does not constitute an adequate and well-controlled clinical investigation providing substantial evidence of effectiveness. The agency cited... More
